Total Payments
$55,000
2024 Payments
$5,561
Companies
75
Transactions
568
Medicare Patients
1,458
Medicare Billing
$250,094
Payment Breakdown by Category
Consulting$21,001 (38.2%)
Food & Beverage$16,298 (29.6%)
Other$14,636 (26.6%)
Travel$1,791 (3.3%)
Education$1,274 (2.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $21,001 | 16 | 38.2% |
| Food and Beverage | $16,298 | 522 | 29.6% |
| Honoraria | $14,636 | 4 | 26.6% |
| Travel and Lodging | $1,791 | 5 | 3.3% |
| Education | $1,274 | 21 | 2.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Rigel Pharmaceuticals, Inc. | $21,817 | 26 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $4,236 | 37 | $0 (2024) |
| TESARO, Inc. | $3,909 | 16 | $0 (2019) |
| Incyte Corporation | $3,508 | 17 | $0 (2024) |
| Sirtex Medical Inc | $3,057 | 7 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $2,055 | 15 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $1,413 | 40 | $0 (2024) |
| Puma Biotechnology, Inc. | $1,279 | 8 | $0 (2023) |
| Janssen Scientific Affairs, LLC | $1,170 | 1 | $0 (2023) |
| Celgene Corporation | $945.61 | 29 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $5,561 | 105 | Incyte Corporation ($2,637) |
| 2023 | $12,875 | 109 | Rigel Pharmaceuticals, Inc. ($5,411) |
| 2022 | $19,343 | 77 | Rigel Pharmaceuticals, Inc. ($16,238) |
| 2021 | $4,697 | 56 | AstraZeneca Pharmaceuticals LP ($2,393) |
| 2020 | $1,222 | 36 | Eisai Inc. ($209.42) |
| 2019 | $3,995 | 84 | Puma Biotechnology, Inc. ($1,125) |
| 2018 | $2,426 | 56 | Bayer HealthCare Pharmaceuticals Inc. ($875.20) |
| 2017 | $4,882 | 45 | TESARO, Inc. ($3,700) |
All Payment Transactions
568 individual payment records from CMS Open Payments — Page 1 of 23
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | ADC Therapeutics America, Inc. | — | Food and Beverage | In-kind items and services | $28.09 | General |
| 12/18/2024 | PFIZER INC. | INLYTA (Drug), PADCEV | Food and Beverage | In-kind items and services | $8.07 | General |
| Category: ONCOLOGY | ||||||
| 12/17/2024 | PFIZER INC. | INLYTA (Drug), PADCEV | Food and Beverage | In-kind items and services | $9.17 | General |
| Category: ONCOLOGY | ||||||
| 12/17/2024 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $7.28 | General |
| Category: ONCOLOGY | ||||||
| 12/16/2024 | Telix Pharmaceuticals | ILLUCCIX (Drug), ILLUCCIX | Food and Beverage | In-kind items and services | $20.49 | General |
| Category: PROSTATE CANCER THERAPY | ||||||
| 12/16/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $19.72 | General |
| Category: Oncology | ||||||
| 12/11/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $20.19 | General |
| Category: Rare Disease | ||||||
| 12/09/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $9.96 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 12/09/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $8.78 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 12/04/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $27.65 | General |
| Category: Oncology | ||||||
| 12/02/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI, TUKYSA | Food and Beverage | In-kind items and services | $27.86 | General |
| Category: ONCOLOGY | ||||||
| 11/27/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $31.55 | General |
| 11/21/2024 | SEAGEN INC. | — | Education | In-kind items and services | $99.95 | General |
| 11/20/2024 | Deciphera Pharmaceuticals Inc. | QINLOCK (Drug) | Food and Beverage | In-kind items and services | $25.25 | General |
| Category: ONCOLOGY | ||||||
| 11/13/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $26.44 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 11/11/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), LYNPARZA | Food and Beverage | In-kind items and services | $26.93 | General |
| Category: ONCOLOGY | ||||||
| 11/06/2024 | ABBVIE INC. | EPKINLY (Drug) | Food and Beverage | In-kind items and services | $10.00 | General |
| Category: ONCOLOGY | ||||||
| 11/04/2024 | Astellas Pharma US Inc | Vyloy (Drug) | Food and Beverage | In-kind items and services | $19.95 | General |
| Category: Oncology | ||||||
| 10/30/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $22.48 | General |
| Category: ONCOLOGY | ||||||
| 10/30/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $4.39 | General |
| Category: ONCOLOGY | ||||||
| 10/28/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $22.11 | General |
| Category: Oncology | ||||||
| 10/21/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $28.18 | General |
| Category: Oncology | ||||||
| 10/16/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Education | In-kind items and services | $77.97 | General |
| Category: ONCOLOGY | ||||||
| 10/15/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $19.71 | General |
| Category: Hematology/Oncology | ||||||
| 10/14/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug), Xofigo | Food and Beverage | In-kind items and services | $31.78 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 255 | 444 | $196,073 | $47,649 |
| 2022 | 7 | 326 | 538 | $234,315 | $60,196 |
| 2021 | 8 | 447 | 701 | $231,400 | $71,624 |
| 2020 | 7 | 430 | 769 | $149,272 | $70,625 |
Total Patients
1,458
Total Services
2,452
Medicare Billing
$250,094
Procedure Codes
28
All Medicare Procedures & Services
28 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 112 | 285 | $115,137 | $28,561 | 24.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 46 | 46 | $31,752 | $7,440 | 23.4% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 32 | 36 | $21,373 | $4,880 | 22.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 20 | 21 | $11,816 | $3,046 | 25.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 29 | 34 | $9,700 | $2,109 | 21.7% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 16 | 22 | $6,294 | $1,612 | 25.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 107 | 277 | $112,484 | $28,987 | 25.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 40 | 40 | $27,733 | $7,218 | 26.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 70 | 101 | $28,921 | $7,167 | 24.8% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 35 | 37 | $22,823 | $5,927 | 26.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 31 | 39 | $22,095 | $5,806 | 26.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 32 | 32 | $16,810 | $4,196 | 25.0% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 11 | 12 | $3,448 | $894.53 | 25.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 158 | 351 | $112,956 | $34,950 | 30.9% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 52 | 60 | $24,000 | $9,707 | 40.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 99 | 122 | $29,306 | $7,920 | 27.0% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 44 | 44 | $25,887 | $7,202 | 27.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 38 | 41 | $17,847 | $6,043 | 33.9% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 32 | 32 | $14,782 | $4,106 | 27.8% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 12 | 16 | $4,871 | $944.48 | 19.4% |
| 96523 | Irrigation of implanted venous access drug delivery device | Office | 2021 | 12 | 35 | $1,750 | $750.82 | 42.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 145 | 378 | $66,150 | $33,276 | 50.3% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 65 | 82 | $31,000 | $13,613 | 43.9% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 110 | 151 | $19,630 | $8,239 | 42.0% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 45 | 45 | $15,210 | $7,341 | 48.3% |
About Dr. Ahmed Nadeem, MD
Dr. Ahmed Nadeem, MD is a Hematology & Oncology healthcare provider based in Woonsocket, Rhode Island. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/06/2006. The National Provider Identifier (NPI) number assigned to this provider is 1952332041.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ahmed Nadeem, MD has received a total of $55,000 in payments from pharmaceutical and medical device companies, with $5,561 received in 2024. These payments were reported across 568 transactions from 75 companies. The most common payment nature is "Consulting Fee" ($21,001).
As a Medicare-enrolled provider, Nadeem has provided services to 1,458 Medicare beneficiaries, totaling 2,452 services with total Medicare billing of $250,094. Data is available for 4 years (2020–2023), covering 28 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Woonsocket, RI
- Active Since 07/06/2006
- Last Updated 09/07/2007
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1952332041
Products in Payments
- Tavalisse (Drug) $16,339
- Rezlidhia (Drug) $5,478
- ZEJULA (Drug) $4,167
- CALQUENCE (Drug) $3,227
- SIR-Spheres Microspheres (Device) $3,057
- Stivarga (Drug) $1,943
- RYBREVANT (Drug) $1,311
- Nerlynx (Drug) $1,159
- OPDIVO (Biological) $828.47
- KEYTRUDA (Biological) $820.50
- Lenvima (Drug) $714.61
- BRUKINSA (Drug) $640.19
- JAKAFI (Drug) $506.49
- REBLOZYL (Biological) $341.34
- VENCLEXTA (Drug) $340.12
- LYNPARZA (Drug) $339.52
- ERLEADA (Drug) $326.78
- PADCEV (Biological) $326.61
- JEVTANA (Drug) $271.25
- XPOVIO (Drug) $259.44
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.